{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/leg-ulcer-venous/diagnosis/interpretation-of-abpi/","result":{"pageContext":{"chapter":{"id":"35ee8784-602e-5a29-9ccf-65b3c3f940d2","slug":"interpretation-of-abpi","fullItemName":"Interpretation of ABPI","depth":2,"htmlHeader":"<!-- begin field 8b73e297-b240-4cc6-9f86-aa9f0011d4c1 --><h2>How should I interpret ankle brachial pressure index (ABPI) results?</h2><!-- end field 8b73e297-b240-4cc6-9f86-aa9f0011d4c1 -->","summary":"","htmlStringContent":"<!-- begin item d9402482-6203-45cc-9e40-aa9f0011d3a4 --><!-- begin field 0686044c-9a9f-4f46-8d04-aa9f0011d4c1 --><p><strong>The ankle brachial pressure index (ABPI) provides an index of vessel competency by measuring the ratio of systolic blood pressure at the ankle to that in the arm, with a value of 1 being normal. Measurement of ABPI should be undertaken by an experienced operator using validated equipment.</strong></p><ul><li><strong>An ABPI ratio of</strong><strong>:</strong><ul><li><strong>Less than 0.5</strong> suggests severe arterial disease.<ul><li>Compression treatment is contraindicated. </li><li><a class=\"topic-reference internal-reference\" href=\"/topics/leg-ulcer-venous/management/venous-leg-ulcers/#when-to-refer\">Refer</a> the person urgently for specialist vascular assessment. </li></ul></li><li><strong>Greater than 0.5 to</strong> <strong>less than 0.8</strong> suggests the presence of arterial disease or mixed arterial/venous disease.<ul><li>Compression should generally be avoided. However, reduced compression can be used under specialist advice and with strict supervision.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/leg-ulcer-venous/management/venous-leg-ulcers/#when-to-refer\">Refer</a> the person for specialist vascular assessment. </li></ul></li><li><strong>Between 0.8 and 1.3</strong> suggests no evidence of significant arterial disease.<ul><li>Compression may be safely applied in most people. </li><li>For people with cardiac failure, consider seeking specialist advice as there may be a risk of fluid overload if not closely monitored. </li></ul></li><li><strong>Greater than 1.3</strong> may suggest the presence of arterial calcification, such as in some people with diabetes, rheumatoid arthritis, systemic vasculitis, atherosclerotic disease, and advanced chronic renal failure. For values above 1.5, the vessels are likely to be incompressible, and the result cannot be relied on to guide clinical decisions.<ul><li>Care must be taken in interpreting ABPI results in people with these conditions, as they may be misleadingly high.</li><li>Compression therapy should be used with caution in people with diabetes, who may have unreliable ABPIs due to arterial calcification as well as an underlying sensory neuropathy.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/leg-ulcer-venous/management/venous-leg-ulcers/#when-to-refer\">Refer</a> to a vascular service as further assessments may be required to determine the person's suitability for compression therapy.</li></ul></li></ul></li><li><strong>ABPI values should always be interpreted in the context of signs and symptoms. </strong>For example, if it is within the normal range but the person has symptoms of peripheral arterial disease (such as intermittent claudication or rest pain), consider <a class=\"topic-reference internal-reference\" href=\"/topics/leg-ulcer-venous/management/venous-leg-ulcers/#when-to-refer\">referral</a> for specialist vascular assessment. </li><li><strong>There is no consensus among guidelines on the frequency of repeat ABPI measurements</strong><strong>. </strong><ul><li>Ideally, Doppler studies should be repeated every 6–12 months (or earlier if clinically indicated).</li><li>In practice, the frequency will be guided by local availability and resources. </li></ul></li></ul><!-- end field 0686044c-9a9f-4f46-8d04-aa9f0011d4c1 --><!-- end item d9402482-6203-45cc-9e40-aa9f0011d3a4 -->","topic":{"id":"627b2b3c-014b-5543-8f89-0f3ffa6344ad","topicId":"4c5db985-9544-48b2-8c54-8915ec210739","topicName":"Leg ulcer - venous","slug":"leg-ulcer-venous","lastRevised":"Last revised in January 2021","chapters":[{"id":"01818c5e-efb9-59c4-b339-08b834294232","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"313e84c5-8bc7-5150-826a-467ea7252acd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2597db24-8ec5-54d4-86ad-8082be50f4f6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"38f24092-0019-582d-86bf-d1f61bccde1d","slug":"changes","fullItemName":"Changes"},{"id":"cdc15e74-0503-53a5-a4be-c53ec4e20898","slug":"update","fullItemName":"Update"}]},{"id":"73d0cf59-f9c0-5785-8c74-e756826d5d1e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"64b11689-d52a-560f-8d9b-c592d654615e","slug":"goals","fullItemName":"Goals"},{"id":"ac3d1637-467f-5edb-8fd8-73f66160080f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4bffe5b2-0ce0-5ae8-8c0b-914bb6ed5a1d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"82441da5-60f5-53b4-b510-187f7bacb4a8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3e5817d5-30e7-54b7-b9ba-224b4a295bba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b30bb006-efbc-5a69-90f3-30abf232a97d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"84dc0da0-8533-5c5d-99f6-7c04a116701a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"45d8d35d-9757-544c-b04e-9747898a1f0e","slug":"definition","fullItemName":"Definition"},{"id":"21acb832-e5e8-5bd1-9b8d-9410ec5011bf","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cf27bd7b-b787-5def-bb40-ee0f134a8aca","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a55a1739-f3d2-534c-b533-f6406d9c81ea","slug":"complications","fullItemName":"Complications"},{"id":"683b612a-3f1d-5580-951b-e14672f52b4a","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"dbc94220-a914-56d0-883d-d158da511e1c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"57b3b7a5-9042-53fa-a236-56d0d02b647e","slug":"assessment","fullItemName":"Assessment"},{"id":"35ee8784-602e-5a29-9ccf-65b3c3f940d2","slug":"interpretation-of-abpi","fullItemName":"Interpretation of ABPI"},{"id":"0c766f2c-0c8f-521b-85fd-e947ba6b2d09","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5e199f8a-7621-5318-9da1-264db8f544b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"c8bda10b-ebb6-533b-9c91-96efa5ddf0c3","slug":"venous-leg-ulcers","fullItemName":"Scenario: Venous leg ulcers"}]},{"id":"e084faba-a409-53ac-aa53-08b80a3991f1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"66a7f656-c6f5-57a2-a08a-1533a6fd4e92","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"a6cda703-9039-5115-b3d3-478cdb4d1e55","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"1cf75cbb-8bc4-58cc-9a1b-11516db5ad2c","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"},{"id":"3f0efc32-779b-56f6-85ca-e46a59745bed","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"fe306aab-d8d7-5181-a461-128f2aa3c65a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"314a80d5-e16b-5625-8d64-4141535ff392","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"b7e7b8ec-799c-5ea5-9ac0-11935f899b8a","slug":"oral-analgesia","fullItemName":"Oral analgesia"},{"id":"43ed3b03-6322-5690-8f85-b6e10a0b3d3e","slug":"pentoxifylline","fullItemName":"Pentoxifylline"}]},{"id":"19f3ffbe-f365-5196-8586-0dceeaf69908","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"89207239-b8a4-50ce-8b2d-3065a830c0af","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"45831e7c-0e6f-50f3-a513-fe4fcacff65e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3d90cdb0-b2fd-5bfd-bd2d-342e36901f9d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8b66d1a4-6ee5-5556-b671-204219a81787","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5b8ee442-8da6-524f-bf34-e6a9cc2a771e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6fa96be3-beae-51f6-9f1c-4d278b058d09","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e75dc366-237b-55d2-a654-2e3bf503b955","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"dbc94220-a914-56d0-883d-d158da511e1c","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"283e18c7-a42d-5539-9005-11efee34c3db","slug":"basis-for-recommendation-4e4","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field eb4bf732-9382-448c-9ba7-aa9f0011d4dd --><h3>Basis for recommendation</h3><!-- end field eb4bf732-9382-448c-9ba7-aa9f0011d4dd -->","summary":null,"htmlStringContent":"<!-- begin item 4e4a3516-8728-452f-8cc3-aa9f0011d4dc --><!-- begin field 4771d5f1-510a-45bd-8528-aa9f0011d4dd --><p>These recommendations are based on the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of chronic venous leg ulcers</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">SIGN, 2010</a>], the Primary Care Dermatology Society (PCDS) guideline <em>Leg ulcers (and disorders of venous insufficiency)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">PCDS, 2016</a>], and the Wounds UK document <em>Best Practice Statement: Addressing complexities in the management of venous leg ulcers</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Wounds UK, 2019</a>].</p><h4>Ankle brachial pressure index (ABPI)</h4><ul><li>The ABPI is the ratio of the ankle systolic blood pressure to the brachial systolic blood pressure and can be measured using a sphygmomanometer and a hand held Doppler device [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">SIGN, 2010</a>].</li><li>It is the most reliable way to detect arterial insufficiency. The absence of foot pulses may indicate arterial insufficiency; however, palpation alone is not sufficient to rule this out [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">SIGN, 2010</a>].</li><li>SIGN advises that the measurement of ABPI should be performed by appropriately trained healthcare practitioners due to the complexity of clinical reporting and methodological issues around interpretation and reproducibility of results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">SIGN, 2010</a>].</li><li>The interpretation of the ABPI ratios is based on the SIGN guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">SIGN, 2010</a>] and the Wound UK document [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Wounds UK, 2019</a>].</li></ul><h4>People with cardiac failure</h4><ul><li>The PCDS advises that caution is needed when using compression in people with cardiac failure as there can be a risk of fluid overload if not closely monitored. Specialist advice and a multidisciplinary approach is often needed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">PCDS, 2016</a>].</li></ul><h4>People with diabetes </h4><ul><li>SIGN recommends that compression therapy should be used with caution in people with diabetes, who may have unreliable ABPI values due to arterial calcification as well as an underlying sensory neuropathy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">SIGN, 2010</a>].</li></ul><h4>People with rheumatoid arthritis or systemic vasculitis </h4><ul><li>SIGN recommends specialist referral at an early stage of management for people with rheumatoid arthritis or systemic vasculitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">SIGN, 2010</a>].</li><li>The PCDS advises that people with rheumatoid arthritis should be referred to a specialist because Dopplers may give falsely high readings, there is often additional small vessel disease, and the long-term medications used for treating rheumatoid arthritis can delay ulcer healing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">PCDS, 2016</a>].</li></ul><h4>Referral if the ABPI is more than 1.3 </h4><ul><li>SIGN advises that care must be taken in interpreting ABPI results in people with heavily calcified vessels, where they may be misleadingly high. For values above 1.5, the vessels are likely to be incompressible, and the result cannot be relied on to guide clinical decisions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">SIGN, 2010</a>].</li><li>Expert opinion in the Wound UK document is that referral to a vascular service or tissue viability team should be considered for all people with ABPI greater than 1.3 as further assessments are required to determine the person’s suitability for compression therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Wounds UK, 2019</a>].</li></ul><!-- end field 4771d5f1-510a-45bd-8528-aa9f0011d4dd --><!-- end item 4e4a3516-8728-452f-8cc3-aa9f0011d4dc -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}